Monocyte activation plays an important role in diabetic complications such as diabetic retinopathy (DR). However, the regulation of monocyte activation in diabetes remains elusive. Fenofibrate, an agonist of peroxisome proliferator-activated receptor-α (PPARα), has shown robust therapeutic effects on DR in patients with type 2 diabetes. Here we found that PPARα levels were significantly downregulated in monocytes from patients with diabetes and animal models, correlating with monocyte activation. Fenofibrate attenuated monocyte activation in diabetes, while PPARα knockout alone induced monocyte activation. Furthermore, monocyte-specific PPARα overexpression ameliorated, while monocyte-specific PPARα knockout aggravated monocyte activation in diabetes. PPARα knockout impaired mitochondrial function while also increasing glycolysis in monocytes. PPARα knockout increased cytosolic mitochondrial DNA release and activation of the cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway in monocytes under diabetic conditions. STING knockout or STING inhibitor attenuated monocyte activation induced by diabetes or by PPARα knockout. These observations suggest that PPARα negatively regulates monocyte activation through metabolic reprogramming and interaction with the cGAS-STING pathway.

Growing evidence suggests that retinal inflammation plays a pathogenic role in diabetic retinopathy (DR) (1). Diabetes can result in leukocyte activation, adhesion to the retina vascular endothelium, and extravasation into the retinal tissue, leading to a chronic inflammatory state of the retina (2). Leukocyte adhesion to retinal vasculature, referred to as leukostasis, has been observed in patients with diabetes and in animal models of diabetes (3,4). Increased leukocyte adhesion contributes to the blood-retinal barrier breakdown, a principal cause of diabetic macular edema (DME) (5,6). Leukostasis can also result in nonperfused capillaries, which leads to retinal ischemia and neovascularization. Thus, leukostasis is the major contributor to DME and neovascularization (7,8).

As a type of leukocyte, monocytes can differentiate into macrophages or myeloid lineage dendritic cells in tissues and are pivotal in endothelium damage in adaptive immunity-related diseases, such as atherogenesis (911). Monocytes from donors with diabetes exhibited increased proatherogenic activities compared with those from control donors (12,13). In addition, monocyte adhesion to the retinal vascular endothelium is an important feature in DR (14,15). However, the regulation of monocyte activation in retinal inflammation and vascular leakage in DR has not been well studied.

The cGAS-STING signaling axis, a major regulator of inflammation, consists of cyclic GMP-AMP synthase (cGAS) and a stimulator of interferon genes (STING) (16). cGAS is a cytosolic DNA sensor that generates 2′,3′-cyclic GMP-AMP (cGAMP) in response to the binding of double-stranded DNA (17). cGAMP binds and activates STING, leading to the activation of a cascade of downstream pathways, including those mediated by TANK-bind kinase 1 (TBK1)/interferon regulatory factor 3 (IRF3), nuclear factor-κB (NF-κB), and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) (1820). Consequently, these pathways upregulate inflammatory cytokines, such as interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α), eliciting innate immune responses. cGAS-STING has been linked with chronic inflammation and cancer progression. However, its association with DR has not been established.

Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor (21). PPARα activates the expression of genes in lipid metabolism and regulates energy homeostasis (22,23). PPARα also inhibits the transcription of inflammatory response genes (24,25). PPARα-deficient mice show a prolonged response to inflammatory stimuli (26,27). Two independent prospective clinical trials reported that fenofibrate, a PPARα agonist, has robust therapeutic effects on DR in patients with type 2 diabetes (28,29). Fenofibrate has a PPARα-dependent anti-inflammatory effect by inhibiting proinflammatory transcription factors, such as NF-κB (30). In addition, fenofibrate reduces retinal vascular leakage in a PPARα-dependent manner in diabetic animal models, which may contribute to its effect on DME in patients with diabetes (31). Recently, Wang et al. (32) identified that PPARα contributed to the aging-induced inflammation in monocytes. However, the function of PPARα in monocytes in diabetes and DR is unknown.

In the present research, we measured PPARα levels in monocytes from patients with diabetes and diabetic animal models. We also investigated the regulatory role of PPARα in monocyte activation and retinal leukostasis in DR models and its interaction with the cGAS-STING pathway.

Patients

The study adhered to the tenets of the Declaration of Helsinki and was approved by the Tianjin Medical University Eye Hospital. Written informed consent was obtained from each patient. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and patients with type 2 diabetes by density gradient centrifugation (Ficoll Paque Plus; Sigma-Aldrich, St. Louis, MO). In some experiments, monocytes were purified from the isolated PBMCs by using a positive monocyte isolation kit (MACS; Miltenyi, Bergisch Gladbach, Germany).

Animals

Male db/db mice, their heterozygous littermates (db/m), male Akita mice, OVE26 mice, STING knockout (KO) mice, PPARα global KO (PPARα−/−) mice, C57BL/6J mice (wild-type [WT] control for PPARα−/− mice), and FVB mice (nondiabetic control of OVE26 mice) were from Jackson Laboratory (Bar Harbor, ME). Male Brown Norway (BN) rats were from Charles River Laboratories (Wilmington, MA). All experiments were performed following the guidelines of the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and approved by the Oklahoma University Health Sciences Center Institutional Animal Care and Use Committee.

Monocyte-Specific PPARα Transgenic Mice and PPARα Conditional KO Mice

The transgenic PPARαflox/flox mouse line was generated using chicken β-actin promoter and a floxed stop cassette through a contracted service with Cyagen Biosciences (Santa Clara, CA). The transgenic PPARαflox/flox mouse line was crossbred with CX3CR1-Cre mice (Jackson Laboratory) to generate monocyte-specific PPARα transgenic mice (PPARαMCTg) overexpressing PPARα.

PPARαflox/flox mice for KO were designed by inserting loxP sites flanking exon 4 of the PPARα gene in Ingenious Targeting Laboratory (Ronkonkoma, NY). To generate monocyte-specific PPARα KO mice (PPARαMCKO), we crossbred PPARαflox/flox mice with CX3CR1-Cre mice.

Streptozotocin-Induced Diabetic Animal Models

BN rats received an intraperitoneal (i.p.) injection of streptozotocin (STZ; 50 mg/kg) after overnight fasting. Blood glucose levels were measured 3 days after the injection. Diabetes was induced in mice with daily i.p. injections of STZ at a dose of 55 mg/kg for 5 consecutive days. Only the animals with glucose levels >350 mg/dL were used as diabetic animals. Animals were fed control rodent chow (5053; LabDiet/TestDiet, Ft. Worth, TX) or the chow containing 0.04% (for rats) and 0.014% (for mice) fenofibrate (Sigma-Aldrich) for 8 weeks (rats) and 12 weeks (mice) from the onset of diabetes.

Retinal Leukostasis Assay

The assay was performed as described previously (33). Briefly, anesthetized mice were perfused with warm PBS, and then adherent leukocytes in the vasculature were stained by perfusion with FITC-conjugated concanavalin-A (ConA; Vector, Burlingame, CA). Extra Con A was washed off by PBS perfusion. Adherent leukocytes were counted in the whole retina under a Zeiss AxioObserver Z1 epi-fluorescent microscope (Carl Zeiss, Göttingen, Germany). Representative images in flat-mounted retinas were collected and presented.

Western Blot Analysis

Monocyte lysate was resolved by SDS-PAGE and immunoblotted with primary antibodies against human PPARα (Affinity; Changzhou, Jiangsu, China), mouse PPARα (Abcam, Waltham, MA), STING (Proteintech Group), cGAS (Cell Signaling Technology, Danvers, MA), and β-actin (Sigma-Aldrich). The band intensities were semiquantified by densitometry using ImageJ software (National Institutes of Health, Bethesda, MD).

Real-Time RT-PCR

Total RNA was isolated from monocytes using TRIzol reagent (Thermo Fisher, Waltham, MA). The quantitative RT-PCR (qRT-PCR) results were normalized against levels of hypoxanthine phosphoribosyl transferase (HPRT) mRNA. The primer sequences were as follows: human PPARα–forward: 5′-ATGGTGGACACGGAAAGCC-3′, human PPARα–reverse: 5′-CGATGGATTGCGAAATCTCTTGG-3′, human HPRT–forward: 5′-CCTGGCGTCGTGAT-TAGTGAT-3′, and human HPRT–reverse: 5′-AGACGTTCAGTCCTGTCCATAA-3′.

Flow Cytometry Analysis

To quantify protein levels of PPARα and STING in monocytes, flow cytometry was used as previously described (34). Briefly, after fixation, cells were incubated with a panel of antibodies against CD11b-BV510 (BioLegend, San Diego, CA) and PPARα (Novus, Centennial, CO), or a panel of antibodies against CD11b conjugated with FITC (101205; BioLegend) and STING (19851-1-AP; Proteintech, Rosemont, IL). The stained cells were counted by Stratedigm S1300Ex (Stratedigm, San Jose, CA), and data were analyzed by FlowJo software (BD Biosciences, Franklin Lakes, NJ).

Endothelial-Monocyte Adhesion Assays

Adhesion analyzed by fluorescence microscopy: Primary mouse brain microvascular endothelial cells (mECs) were isolated and purified by puromycin from 3- to 4-week-old mice following a published protocol (35). mEC purity was verified by immunofluorescence using an antibody against CD31 (Supplementary Fig. 1). mECs at passages 1–2 or primary human retinal capillary ECs (HRCECs; Cell Systems, Kirkland, WA) were seeded in 6-well plates and allowed to reach confluence. ECs were incubated with or without 2 ng/mL TNF-α for 6 h at 37°C. Freshly isolated PBMCs were incubated with the EC monolayer for 6 h at 37°C. After nonadherent cells were removed, adherent cells were fixed with 4% paraformaldehyde, stained with DAPI, and visualized under a fluorescent microscope. Digital images from five random high-power fields (HPFs) were taken using the Biotek Cytation1 microscope (Agilent, Santa Clara, CA). Adhered cells per HPF were counted using the ImageJ software. The result was presented as adherent cell numbers per field.

Adhesion analyzed by flow cytometry: Briefly, PBMCs were labeled with 2′,7′-bis (2-carboxyethyl)-5(6)-carboxy-fluorescein acetoxymethyl ester (BCECF/AM; Thermo Fisher) and then were incubated with the TNF-α–treated EC monolayer for 6 h at 37°C. After nonadherent cells were removed, the adherent cells were trypsinized, resuspended, and transferred into test tubes (Falcon 5 mL Round Bottom Polystyrene Test Tube) for flow cytometry analysis. Next, cells were loaded on FACS LSR II flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo (BD Biosciences). The result was presented as the percentage of monocytes in the total cell suspension, including ECs and PBMCs.

Cell Migration Assays

Monocytes were seeded into the upper chamber of 6.5-mm polycarbonate membrane inserts with 3.0 μm-diameter pores (Corning, Corning, NY) and incubated for 6 h. Cells were fixed with 70% methanol and stained with hematoxylin-eosin. After cells on the top were removed, membranes were air dried for 1 h, separated with the Transwell inserts, and mounted on a glass slide. Cells migrating through the membrane were imaged for five random HPFs using an Olympus BX43 microscope (Olympus, Tokyo, Japan). The migrated cells of each membrane were counted using ImageJ software and averaged from the five images.

Phagocytosis Assays

After being incubated with 20 mg/L FITC-conjugated dextran (40 kDa; Molecular Probes, Life Technologies, Carlsbad, CA) for 30 min at 37°C, cells were washed and fixed in 4% paraformaldehyde. Average fluorescence intensities and the percentages of dextran-positive cells were determined by flow cytometry.

mtDNA Cytosolic Release

Cytosolic and nuclear fractions were isolated using the Cell Fractionation kit (Thermo Fisher) according to the manufacturer’s protocol. The cytosolic mtDNA was quantified by measuring mitochondrial gene cytochrome c oxidase 1 using real-time PCR and normalized by a chromosome gene, β-actin. The following primers were used: cytochrome c oxidase 1–forward: 5′-TCGGAGCCCCAGATATAGCA-3′ and reverse: 5′-TTTCCGGCTAGAGGTGGGTA-3′; and β-actin–forward: 5′-ACCTTCTACAATGAGCTGCG-3′ and reverse: 5′-CTGGATGGCTACGTACATGG-3′.

Metabolic Profile Analysis

Analysis of the metabolic profile in monocytes was performed via a Seahorse XFe96 Flux Analyzer (Agilent, Santa Clara, CA). A Seahorse XF Cell Mito Stress Test kit (Agilent) was used to record the oxygen consumption rate (OCR; oligomycin 1 μmol/L, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone [FCCP] 2 μmol/L, rotenone and antimycin A [RAA] 1 μmol/L). The extracellular acidification rate (ECAR) was studied by a Seahorse XF Glycolysis Stress Test kit (Agilent) with glucose 10 mmol/L, oligomycin 1.0 μmol/L, and 2-deoxy-d-glucose 50 mmol/L. Mitochondrial function and glycolysis were calculated and compared according to the manufacturer’s instructions.

Statistical Analysis

All experiments were performed at least three times independently. Quantitative data are presented as mean ± SD and were analyzed by Student t test for comparison of two groups and by ANOVA for comparison of more than two groups.

Data and Resource Availability

Data and resources are available upon request. For original data, please contact [email protected].

Decreased PPARα Levels in Diabetic Monocytes

As shown in Fig. 1A–C, both the protein and mRNA levels of PPARα were significantly decreased in monocytes from patients with diabetes relative to subjects without diabetes, as shown by Western blot and qRT-PCR analyses (Fig. 1A–C). PPARα levels were also downregulated in monocytes from type 1 diabetic models, including STZ-induced diabetic rats (Fig. 1D and E), OVE26 mice (a genetic type 1 diabetic model) (Fig. 1F and G), STZ-induced diabetic mice (Fig. 1H and I), and a type 2 diabetic model, db/db mice (Fig. 1J and K). The CD11b+/PPARα+ monocyte count was significantly decreased in diabetic rats. Conversely, fenofibrate, an agonist of PPARα, significantly increased the CD11b+/PPARα+ monocytes population in diabetic rats (Fig. 1L and M). Similarly, the numbers of CD11b+/PPARα+ monocytes in STZ-diabetic mice fed fenofibrate chow were higher than in diabetic mice fed regular chow (Fig. 1N and O). The results suggested that fenofibrate attenuated diabetes-induced downregulation of PPARα in monocytes.

Figure 1

Decreased PPARα in monocytes from patients with diabetes and animal models. A: A representative Western blot of PPARα in monocytes from patients with diabetes (DM) and without diabetes (NDM) (n = 6). B: PPARα levels were quantified by densitometry and normalized by actin levels. C: PPARα mRNA levels were measured by qRT-PCR in monocytes from patients with diabetes and normalized with HPRT (n = 20). Representative flow cytometry plots and quantification of PPARα+ monocytes (CD11b+/PPARα+ cells) in diabetic rats (DM/STZ-Rat, 6 months of diabetes) (D and E), OVE26 mice (OVE) at 6 months of age in FVB background (F and G), C57BL/6J mice with 8 weeks of STZ-induced diabetes (DM/STZ-Mouse) (H and I), and 6-month-old db/db mice (J and K). Representative flow cytometry plots of STZ-induced diabetic rats (L) and mice treated with chow containing fenofibrate (FF) (N), and quantification of PPARα+ cells from the rats (M) and mice (O). Data are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Figure 1

Decreased PPARα in monocytes from patients with diabetes and animal models. A: A representative Western blot of PPARα in monocytes from patients with diabetes (DM) and without diabetes (NDM) (n = 6). B: PPARα levels were quantified by densitometry and normalized by actin levels. C: PPARα mRNA levels were measured by qRT-PCR in monocytes from patients with diabetes and normalized with HPRT (n = 20). Representative flow cytometry plots and quantification of PPARα+ monocytes (CD11b+/PPARα+ cells) in diabetic rats (DM/STZ-Rat, 6 months of diabetes) (D and E), OVE26 mice (OVE) at 6 months of age in FVB background (F and G), C57BL/6J mice with 8 weeks of STZ-induced diabetes (DM/STZ-Mouse) (H and I), and 6-month-old db/db mice (J and K). Representative flow cytometry plots of STZ-induced diabetic rats (L) and mice treated with chow containing fenofibrate (FF) (N), and quantification of PPARα+ cells from the rats (M) and mice (O). Data are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Close modal

Attenuated Monocyte Activation in Diabetic Animals by PPARα

As shown by the leukostasis assay, the retinas from the STZ-induced diabetic mice showed increased leukocytes adherent to retinal capillaries relative to nondiabetic retinas, and fenofibrate oral treatment reduced diabetes-induced leukocyte adhesion in the retina (Fig. 2A and B). In vitro leukocyte adhesion assays by cell counting (Fig. 2C and D) and flow cytometry (Fig. 2E and F) both demonstrated that monocytes isolated from diabetic mice showed enhanced adhesion to HRCECs compared with monocytes from nondiabetic mice. Monocytes from diabetic mice fed fenofibrate showed decreased adherence to HRCECs compared with those from diabetic mice fed regular chow (Fig. 2C–F). These results suggested that PPARα activation alleviates leukostasis in the diabetic retina.

Figure 2

Attenuated monocyte adhesion and migration by fenofibrate in STZ-induced diabetic mice. Nondiabetic mice (NDM) and STZ-induced diabetic mice (DM) were fed chow containing 0.014% fenofibrate (FF) for 12 weeks, with regular chow as the control. A: Representative images of FITC-ConA–labeled adherent leukocytes in retinal vessels (indicated by arrows). Scale bar = 100 µm. B: Quantification of adherent leukocytes in the retina. CF: PBMCs were isolated and labeled with BCECF-AM and then cocultured with an HRCEC monolayer. After thorough washes, the attached monocytes were analyzed by DAPI staining (C and D) or flow cytometry analysis (E and F). SSC, side scatter. Scale bar = 20 μm. G and H: PBMCs were fed with FITC–dextran-70, and cells with phagocytosis were quantified by flow cytometry. I and J: The cells were cultured in Transwell with a 3.0-µm pore membrane insert. The cells that penetrated through the membrane were stained with hematoxylin-eosin and quantified. Scale bar = 100 μm. KN: PBMCs were isolated from WT and PPARα−/− (PKO) mice with 8 weeks of STZ-induced diabetes (DM) and their age-matched nondiabetic mice (NDM). PBMCs were labeled with BCECF-AM, and monocytes adherent to HRCECs were analyzed by flow cytometry (K) or DAPI staining (L). M: Phagocytosis was examined by flow cytometry after the cells were incubated with FITC–dextran-70. N: Cell migration was quantified using the Transwell assay. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Figure 2

Attenuated monocyte adhesion and migration by fenofibrate in STZ-induced diabetic mice. Nondiabetic mice (NDM) and STZ-induced diabetic mice (DM) were fed chow containing 0.014% fenofibrate (FF) for 12 weeks, with regular chow as the control. A: Representative images of FITC-ConA–labeled adherent leukocytes in retinal vessels (indicated by arrows). Scale bar = 100 µm. B: Quantification of adherent leukocytes in the retina. CF: PBMCs were isolated and labeled with BCECF-AM and then cocultured with an HRCEC monolayer. After thorough washes, the attached monocytes were analyzed by DAPI staining (C and D) or flow cytometry analysis (E and F). SSC, side scatter. Scale bar = 20 μm. G and H: PBMCs were fed with FITC–dextran-70, and cells with phagocytosis were quantified by flow cytometry. I and J: The cells were cultured in Transwell with a 3.0-µm pore membrane insert. The cells that penetrated through the membrane were stained with hematoxylin-eosin and quantified. Scale bar = 100 μm. KN: PBMCs were isolated from WT and PPARα−/− (PKO) mice with 8 weeks of STZ-induced diabetes (DM) and their age-matched nondiabetic mice (NDM). PBMCs were labeled with BCECF-AM, and monocytes adherent to HRCECs were analyzed by flow cytometry (K) or DAPI staining (L). M: Phagocytosis was examined by flow cytometry after the cells were incubated with FITC–dextran-70. N: Cell migration was quantified using the Transwell assay. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Close modal

The phagocytic activity was compared on monocytes from STZ-induced diabetic mice and age-matched nondiabetic mice fed fenofibrate chow or regular chow. As shown by flow cytometry, relative to the isolated nondiabetic monocytes, diabetic monocytes showed enhanced phagocytosis activity, and the diabetes-induced phagocytosis was attenuated by fenofibrate treatment (Fig. 2G and H).

Monocyte migration was measured using a Transwell assay. Compared with monocytes from nondiabetic mice, STZ-diabetic monocytes showed increased migration rates. Fenofibrate chow significantly alleviated diabetes-induced monocyte migration (Fig. 2I and J). However, fenofibrate did not affect the activities of monocytes under nondiabetic conditions (Fig. 2).

Diabetic PPARα global KO (PPARα−/−) mouse monocytes demonstrated potent adhesion activity to HRCECs relative to diabetic WT monocytes (Fig. 2K and L). Phagocytosis and migration activities were also enhanced in diabetic PPARα−/− monocytes compared with diabetic WT cells (Fig. 2M and N). The deficiency of PPARα did not change monocyte activities under nondiabetic conditions. Taken together, these results indicate that PPARα attenuates the activation of monocytes in diabetic conditions.

A PPARα-Dependent Effect of Fenofibrate on Inhibition of Monocyte Activation

The effects of fenofibrate on PPARα−/− monocytes and WT monocytes were compared. Fenofibrate suppressed monocyte adhesion (Fig. 3A–D), phagocytosis (Fig. 3E and F), and migration (Fig. 3G) in diabetic WT mice. However, fenofibrate had no inhibitory effect on activation of diabetic PPARα−/− monocytes (Fig. 3A–G), suggesting that the effect of fenofibrate on diabetes-activated monocytes was through a PPARα-dependent mechanism.

Figure 3

The impact of fenofibrate on monocyte activation is PPARα dependent. AD: STZ-induced diabetic (WT) and PPARα−/− (PKO) mice were fed fenofibrate (FF) chow for 12 weeks. Monocytes adherent to HRCECs were analyzed by flow cytometry (A and B) and by DAPI staining (C and D). SSC, side scatter. Scale bar = 20 μm. E and F: Phagocytosis was examined by flow cytometry after the cells were incubated with FITC–dextran-70. G: Cell migration was quantified using the Transwell assay. HK: PBMCs were treated with FA in the presence and absence of 4HNE (10 μmol/L) for 6 h. BCECF-AM–labeled monocytes adherent to HRCECs were analyzed by flow cytometry (H) and cell counting under a fluorescent microscope (I). J: The cells were fed FITC–dextran-70, and phagocytosis was quantified by flow cytometry. K: Cell migration was quantified using the Transwell assay. LO: PBMCs from WT and PPARα−/− (PKO) mice were treated with FA in the presence and absence of 4HNE for 6 h. BCECF-AM–labeled monocytes adherent to HRCECs were analyzed and quantified using flow cytometry (L) and cell counting under a microscope (M). N: The cells were fed FITC–dextran-70, and phagocytosis was quantified by flow cytometry. O: Transmigrated monocytes were quantified. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Figure 3

The impact of fenofibrate on monocyte activation is PPARα dependent. AD: STZ-induced diabetic (WT) and PPARα−/− (PKO) mice were fed fenofibrate (FF) chow for 12 weeks. Monocytes adherent to HRCECs were analyzed by flow cytometry (A and B) and by DAPI staining (C and D). SSC, side scatter. Scale bar = 20 μm. E and F: Phagocytosis was examined by flow cytometry after the cells were incubated with FITC–dextran-70. G: Cell migration was quantified using the Transwell assay. HK: PBMCs were treated with FA in the presence and absence of 4HNE (10 μmol/L) for 6 h. BCECF-AM–labeled monocytes adherent to HRCECs were analyzed by flow cytometry (H) and cell counting under a fluorescent microscope (I). J: The cells were fed FITC–dextran-70, and phagocytosis was quantified by flow cytometry. K: Cell migration was quantified using the Transwell assay. LO: PBMCs from WT and PPARα−/− (PKO) mice were treated with FA in the presence and absence of 4HNE for 6 h. BCECF-AM–labeled monocytes adherent to HRCECs were analyzed and quantified using flow cytometry (L) and cell counting under a microscope (M). N: The cells were fed FITC–dextran-70, and phagocytosis was quantified by flow cytometry. O: Transmigrated monocytes were quantified. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Close modal

As a product of lipid peroxidation, 4-hydroxy-2-nonenal (4HNE) is commonly used as a stressor of diabetes in vitro. 4HNE significantly induced cell adhesion (Fig. 3H and I), phagocytosis (Fig. 3J), and migration (Fig. 3K) in primary monocytes from WT mice. Fenofibric acid (FA), an active metabolite of fenofibrate, significantly attenuated the activation of monocytes induced by 4HNE but not under the unstressed control condition (Fig. 3H–L).

Primary monocytes from age-matched WT mice or PPARα−/− mice were isolated and treated with 4HNE. PPARα deficiency dramatically exacerbated 4HNE-induced adhesion, phagocytosis, and migration of monocytes compared with those in WT monocytes (Fig. 3L–O). FA significantly reduced adhesion (Fig. 3L and M), phagocytosis (Fig. 3N), and migration (Fig. 3O) in 4HNE-treated monocytes from WT mice, but not in those from PPARα−/− mice.

PPARα−/− Monocytes Showed Increased Adhesion to WT ECs

To determine whether PPARα, expressed in monocytes or in ECs, plays a significant role in regulating monocyte-EC adhesion, we incubated PPARα−/− ECs with WT monocytes, WT ECs with PPARα−/− monocytes, WT EC with WT monocytes, and PPARα−/− ECs with PPARα−/− monocytes side by side. As shown in Fig. 4A–D, cocultures of PPARα−/− ECs with WT monocytes and WT ECs with PPARα−/− monocytes showed increased adhesion compared with the incubation of WT monocytes with WT ECs, suggesting that PPARα deficiency in either monocytes or ECs promoted monocyte-EC adhesion. Moreover, incubation of PPARα−/− monocytes with PPARα−/− ECs showed the highest adhesion increases among the experimental groups.

Figure 4

Impacts of PPARα deficiency in ECs and monocytes (MCs) on adhesion. PBMCs and primary brain ECs were isolated from age-matched WT and PPARα−/− (PKO) mice. BCECF-AM–labeled WT and PKO MCs were incubated with WT and PPARα−/− ECs. Monocytes adherent to ECs were quantified by cell count (A and B) and flow cytometry (C and D). SSC, side scatter. Scale bar = 20 μm. EJ: PBMCs isolated from PPARαMCKO (MCKO), PPARαMCTg (MCTg), and WT mice were immunostained for PPARα and the monocyte marker CD11b-BV510. E and F: PPARα levels in monocytes were analyzed by flow cytometry. After exposure to 10 μmol/L 4HNE for 6 h, monocytes adherent to ECs were quantified using cell counting (G) or flow cytometry (H). I: Monocyte phagocytosis was analyzed by flow cytometry. J: Monocyte migration was quantified using the Transwell assay. K: Adherent leukocytes in retinal vessels were labeled by FITC-ConA. The leukocyte numbers were quantified and compared between diabetic (DM) WT, PPARαMCKO, and PPARαMCTg mice at 12 weeks after the diabetic onset. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Figure 4

Impacts of PPARα deficiency in ECs and monocytes (MCs) on adhesion. PBMCs and primary brain ECs were isolated from age-matched WT and PPARα−/− (PKO) mice. BCECF-AM–labeled WT and PKO MCs were incubated with WT and PPARα−/− ECs. Monocytes adherent to ECs were quantified by cell count (A and B) and flow cytometry (C and D). SSC, side scatter. Scale bar = 20 μm. EJ: PBMCs isolated from PPARαMCKO (MCKO), PPARαMCTg (MCTg), and WT mice were immunostained for PPARα and the monocyte marker CD11b-BV510. E and F: PPARα levels in monocytes were analyzed by flow cytometry. After exposure to 10 μmol/L 4HNE for 6 h, monocytes adherent to ECs were quantified using cell counting (G) or flow cytometry (H). I: Monocyte phagocytosis was analyzed by flow cytometry. J: Monocyte migration was quantified using the Transwell assay. K: Adherent leukocytes in retinal vessels were labeled by FITC-ConA. The leukocyte numbers were quantified and compared between diabetic (DM) WT, PPARαMCKO, and PPARαMCTg mice at 12 weeks after the diabetic onset. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Close modal

Using the Cre-lox system, we generated tamoxifen-induced monocyte-specific conditional PPARα KO (PPARαMCKO) and PPARα transgenic (PPARαMCTg) mouse lines. Flow cytometry results verified that the CD11b+/PPARα+ cell count was lower in PPARαMCKO mice and was higher in PPARαMCTg mice than in age-matched WT mice (Fig. 4E and F). 4HNE induced a further increase in cell adhesion from PPARαMCKO monocytes but fewer adherent monocytes from the PPARαMCTg mice relative to WT mice (Fig. 4G and H). PPARαMCKO significantly promoted, while PPARαMCTg decreased 4HNE-induced monocytic phagocytosis (Fig. 4I) and migration (Fig. 4J) compared with that in WT mice. We also induced diabetes in PPARαMCKO, PPARαMCTg, and age-matched WT mice. At 12 weeks after diabetes onset, retinal leukostasis was examined and compared between groups. Compared with the diabetic WT group, diabetic PPARαMCKO mice showed significant increases in leukocytes adherent to retinal capillaries, and PPARα overexpression in PPARαMCTg monocytes attenuated diabetes-induced retinal leukostasis (Fig. 4K).

PPARα KO Aggravated STING Activation in Diabetic Monocytes

The cGAS-STING pathway is crucial for inflammation modulation. However, there is no previous evidence implicating the cGAS-STING pathway in DR. To explore the role of the cGAS-STING pathway in DR and its interaction with PPARα, we examined STING levels in monocytes by flow cytometry (Fig. 5A and B). Diabetic mice showed significantly increased STING+ monocytes (CD11b+/STING+ cells) relative to nondiabetic mice (Fig. 5A and B). Furthermore, cGAS and STING protein levels were dramatically upregulated in diabetic monocytes relative to nondiabetic monocytes (Fig. 5C and D). As mtDNA release into the cytosol is a key inducer of the cGAS-STING activation, we quantified cytosolic mtDNA by qRT-PCR. As shown in Fig. 5E, hyperglycemia induced mtDNA cytosolic leakage in monocytes relative to the nondiabetic group.

Figure 5

PPARα KO aggravated STING activation in diabetic monocytes. STZ-induced diabetic WT and PPARα−/− (PKO) mice were fed chow containing 0.014% fenofibrate for 12 weeks. A: The representative image of CD11b+/STING+ cells (STING+ cells) analyzed by flow cytometry. B: STING expression in monocytes was analyzed by flow cytometry. DM, diabetes; NDM, no diabetes. C and D: cGAS and STING levels were measured using Western blot analysis in the isolated monocytes. E: Levels of cytosolic mtDNA were measured by qRT-PCR in monocytes. Adhesion of monocytes of WT and STING−/− (SKO) mice to HRCECs was analyzed by DAPI staining (F and G) and by flow cytometry analysis (H). Scale bar = 20 μm. Quantification of adherent leukocytes in the retina vasculature of db/db (I) and Akita (J) mice treated with C-176. Veh., vehicle control. K: The STING-positive cells in 4HNE-treated WT and PKO monocytes with/without FA were quantified by flow cytometry. L and M: Monocytic cGAS and STING levels were measured using Western blot analysis. N: Levels of cytosolic mtDNA were measured by qRT-PCR in isolated monocytes. O–R: PBMCs isolated from WT and PKO mice were treated with C-176 and 4HNE, labeled with BCECF-AM, and then cocultured with an HRCEC monolayer. O and P: The adherent monocytes were analyzed by flow cytometry. Q and R: The cells were fed with FITC–dextran-70, and phagocytosis was quantified by flow cytometry. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Figure 5

PPARα KO aggravated STING activation in diabetic monocytes. STZ-induced diabetic WT and PPARα−/− (PKO) mice were fed chow containing 0.014% fenofibrate for 12 weeks. A: The representative image of CD11b+/STING+ cells (STING+ cells) analyzed by flow cytometry. B: STING expression in monocytes was analyzed by flow cytometry. DM, diabetes; NDM, no diabetes. C and D: cGAS and STING levels were measured using Western blot analysis in the isolated monocytes. E: Levels of cytosolic mtDNA were measured by qRT-PCR in monocytes. Adhesion of monocytes of WT and STING−/− (SKO) mice to HRCECs was analyzed by DAPI staining (F and G) and by flow cytometry analysis (H). Scale bar = 20 μm. Quantification of adherent leukocytes in the retina vasculature of db/db (I) and Akita (J) mice treated with C-176. Veh., vehicle control. K: The STING-positive cells in 4HNE-treated WT and PKO monocytes with/without FA were quantified by flow cytometry. L and M: Monocytic cGAS and STING levels were measured using Western blot analysis. N: Levels of cytosolic mtDNA were measured by qRT-PCR in isolated monocytes. O–R: PBMCs isolated from WT and PKO mice were treated with C-176 and 4HNE, labeled with BCECF-AM, and then cocultured with an HRCEC monolayer. O and P: The adherent monocytes were analyzed by flow cytometry. Q and R: The cells were fed with FITC–dextran-70, and phagocytosis was quantified by flow cytometry. All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant difference.

Close modal

To study the role of monocytic cGAS-STING signaling in monocyte adhesion, we cocultured HRCECs with monocytes from WT or STING−/− mice, with or without 4HNE exposure. As shown in Fig. 5F–H, in the absence of 4HNE, there was no significant difference between WT and STING−/− monocytes in adherence to HRCECs. 4HNE significantly promoted WT monocyte adhesion. In contrast, 4HNE induced less adhesion in STING−/− monocytes relative to WT monocytes (Fig. 5F–H). A STING inhibitor, C-176 (Cayman Chemical, no. 25859), was used to determine the role of cGAS-STING signaling in monocyte activation in Akita mice (10 weeks of age) and db/db mice aged 12 weeks. Animals received C-176 by daily i.p. injections at the dose of 750 nmol for 14 days, with corn oil as the vehicle control. C-176 significantly reduced the adherent leukocyte number in the retinas of db/db and Akita mice (Fig. 5I and J). In vitro experiments using isolated monocytes also showed that C-176 blocked the 4HNE-induced WT monocyte adhesion (Fig. 5O and P) and phagocytosis (Fig. 5Q and R). These data indicated that the cGAS-STING pathway plays an essential role in monocyte activation in diabetes.

The interaction between PPARα and cGAS-STING signaling is previously unknown. Diabetic PPARα−/− mice showed more prominent STING upregulation in monocytes relative to diabetic WT mice (Fig. 5B). Fenofibrate oral treatment reduced the monocytic STING expression in diabetic WT mice but not in diabetic PPARα−/− mice (Fig. 5B). Further, PPARα KO resulted in upregulation in monocytic STING levels in nondiabetic mice (Fig. 5B).

PPARα−/− monocytes also showed significantly higher levels of cGAS and STING than that of WT monocytes (Fig. 5L and M). 4HNE induced further STING upregulation in PPARα−/− monocytes compared with WT monocytes, and FA reduced the upregulation of STING in monocytes from WT monocytes but not in PPARα−/− monocytes (Fig. 5K). qRT-PCR showed dramatically elevated cytosolic mtDNA leakage in PPARα−/− monocytes relative to WT monocytes (Fig. 5N). 4HNE induced a more prominent increase in adherent and phagocytosis in PPARα−/− monocytes, which was inhibited by C-176 (Fig. 5O–R). This result suggested that PPARα KO resulted in mitochondrial damage and activation of the cGAS-STING pathway, leading to monocyte activation.

Decreased Mitochondrial Function and Increased Glycolysis in PPARα−/− Monocytes

To elucidate the mechanism by which PPARα regulates the cGAS-STING pathway and monocyte activation, we measured the metabolism of monocytes using a Seahorse XF96 analyzer. The basal mitochondrial respiration, maximal mitochondrial respiration, mitochondrial ATP generation, and spare mitochondrial respiration were calculated using real-time OCR values. Compared with those in diabetic WT mice, diabetic PPARα−/− monocytes showed a decreased basal respiration rate (Supplementary Fig. 2A) and ATP generation (Fig. 6A and E), suggesting impaired oxidative phosphorylation in diabetic PPARα−/− monocytes (Supplementary Table 4). Furthermore, the maximal respiration capacity (Fig. 6D) and spare respiration capacity (Supplementary Fig. 2B) also declined in diabetic PPARα−/− monocytes, suggesting that PPARα deficiency exacerbated mitochondrial damage in diabetic monocytes. Meanwhile, diabetic PPARα−/− monocytes showed elevated glycolysis, including increased glycolysis level (Fig. 6I and L), glycolytic capacity (Fig. 6M), and glycolytic reserve (Supplementary Fig. 2H and Supplementary Table 4), suggesting that PPARα deficiency in monocytes resulted in a metabolism switch from mitochondrial oxidative phosphorylation to glycolysis. Fenofibrate effectively preserved the monocytic mitochondrial function in diabetic mice (Fig. 6B, F, and G and Supplementary Fig. 2C and D) and attenuated glycolysis (Fig. 6J, N, and O and Supplementary Fig. 2I). However, fenofibrate showed no effect on monocyte metabolism in diabetic PPARα−/− mice (Fig. 6C, H, K, and P, Supplementary Fig. 2EG, J, and K, and Supplementary Table 4), suggesting that PPARα activation preserved the homeostasis of energy metabolism and the protective effect of fenofibrate on monocytic metabolism is PPARα dependent.

Figure 6

Decreased mitochondrial oxidation and increased glycolysis in monocytes from diabetic PPARα−/− mice. Monocytes isolated from diabetic (DM-WT) and diabetic PPARα−/− (DM-PKO) mice, with or without fenofibrate (FF) chow, were used for mitochondrial and glycolytic assays using a Seahorse XFe96 Analyzer. The data were normalized by cell numbers. AH: OCR (pmol/min/1,000 cells): representative traces of OCR (AC) and quantification of maximal respiration rate and ATP production (DH). Resp., respiration rate. Glycolysis: representative traces of extracellular acidification rate (ECAR; mpH/min/1,000 cells) (IK), and glycolysis and glycolytic capacity (LP). All values are mean ± SD (n = 6). **P < 0.01; ***P < 0.001; ns, no significant difference.

Figure 6

Decreased mitochondrial oxidation and increased glycolysis in monocytes from diabetic PPARα−/− mice. Monocytes isolated from diabetic (DM-WT) and diabetic PPARα−/− (DM-PKO) mice, with or without fenofibrate (FF) chow, were used for mitochondrial and glycolytic assays using a Seahorse XFe96 Analyzer. The data were normalized by cell numbers. AH: OCR (pmol/min/1,000 cells): representative traces of OCR (AC) and quantification of maximal respiration rate and ATP production (DH). Resp., respiration rate. Glycolysis: representative traces of extracellular acidification rate (ECAR; mpH/min/1,000 cells) (IK), and glycolysis and glycolytic capacity (LP). All values are mean ± SD (n = 6). **P < 0.01; ***P < 0.001; ns, no significant difference.

Close modal

PPARα Affected Mitochondrial and Glycolytic Profiles in Monocytes in Diabetic Conditions

4HNE induced a more prominent metabolism switch in PPARα−/− monocytes relative to WT monocytes, as reflected by declined mitochondrial function (Fig. 7A and B, Supplementary Fig. 3A and B, and Supplementary Table 5) and increased glycolysis (Fig. 7F and G, Supplementary Fig. 3H, and Supplementary Table 5). FA prevented 4HNE-induced metabolism change (Fig. 7C, D, H, and I, Supplementary Fig. 3C, D, and I, and Supplementary Table 5) only in WT monocytes but not in PPARα−/− monocytes (Fig. 7E and J, Supplementary Fig. 3EG, J, and K, and Supplementary Table 5) exposed to 4HNE. Taken together, these data indicated that PPARα prevented metabolic profile change and protected mitochondria in monocytes under diabetic conditions, which regulates the cGAS-STING pathway and monocyte activation (Fig. 7K).

Figure 7

Decreased mitochondrial oxidation and increased glycolysis in PPARα−/− monocytes exposed to 4HNE. Monocytes were isolated from PPARα−/− mice (PKO) and WT littermates. The cells were exposed to 4HNE, with and without FA, for 6 h and then used for assays of mitochondrial oxidation and glycolysis. AE: Maximal respiration (Resp.) rate and ATP production (pmol/min/1,000 cells). FJ: Glycolysis and glycolytic capacity (mpH/min/1,000 cells). All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ns, no significant difference. K: Hypothesized mechanism for cGAS-STING signaling activation and monocyte adhesion by PPARα downregulation in diabetes. CTGF, connective tissue growth factor; ICAM, intracellular adhesion molecule.

Figure 7

Decreased mitochondrial oxidation and increased glycolysis in PPARα−/− monocytes exposed to 4HNE. Monocytes were isolated from PPARα−/− mice (PKO) and WT littermates. The cells were exposed to 4HNE, with and without FA, for 6 h and then used for assays of mitochondrial oxidation and glycolysis. AE: Maximal respiration (Resp.) rate and ATP production (pmol/min/1,000 cells). FJ: Glycolysis and glycolytic capacity (mpH/min/1,000 cells). All values are mean ± SD (n = 6). *P < 0.05; **P < 0.01; ns, no significant difference. K: Hypothesized mechanism for cGAS-STING signaling activation and monocyte adhesion by PPARα downregulation in diabetes. CTGF, connective tissue growth factor; ICAM, intracellular adhesion molecule.

Close modal

The current study identified for the first time that the expression of PPARα was downregulated in monocytes from patients with diabetes and diabetic rodent models. Our results also demonstrated that PPARα in monocytes plays a crucial role in regulating monocyte activation and retinal leukostasis. Using monocyte-specific conditional PPARα KO and transgenic mice, we have shown that PPARα attenuated retinal leukostasis through suppressing diabetes-induced monocyte activation. Deficiency of PPARα in monocytes resulted in a disturbed metabolism profile with declined mitochondrial function and increased glycolysis, which contributed to the monocyte activation in diabetes. We also demonstrated for the first time that PPARα deficiency contributed to the cGAS-STING pathway activation in diabetic monocytes, likely through increasing the cytosolic release of mtDNA in monocytes. These findings suggest that diabetes-induced PPARα downregulation results in mitochondrial damage and mtDNA release, leading to activation of the cGAS-STING pathway in monocytes and leukostasis in the retina. These results identified a novel interaction between PPARα and the cGAS-STING pathway in diabetic complications. This study suggests that attenuation of monocyte activation represents a new mechanism for the therapeutic effect of fenofibrate on DR.

DR is considered a chronic inflammatory disorder (36). Leukocyte adherence to retinal vasculature or leukostasis contributes to retinal inflammation, blood-retinal barrier breakdown, and DME (1,36). Most previous studies of DR focused on retinal cells, such as retinal ECs and Müller cells (31,37). The current study identified an important role of monocyte activation in retinal inflammation in DR. Our previous studies identified that the expression of PPARα is downregulated in the retinas of DR patients and DR animal models (30,38). PPARα in ECs exerts protective effects against DR by reducing reactive oxygen species production and inhibiting inflammation-related signaling pathways (31,34,38). However, the role of PPARα in monocyte activation has not been studied previously. Monocytes are activated in diabetes and adhere to the vascular endothelium (retinal leukostasis). Increased retinal leukostasis promotes endothelium dysfunction (14,36). Here, we provide evidence that PPARα levels in monocytes are significantly decreased in both patients with diabetes and in diabetic animal models. Using PPARα KO and agonist, we studied monocyte adhesion by both in vivo (retinal leukostasis) and in vitro (using TNF-α–pretreated HRCECs) experiments. Because of the methodology, the effects of fenofibrate on monocyte adhesion were different between the in vivo leukostasis assay and the in vitro cell adhesion assay. However, the results from both experiments consistently demonstrated that PPARα confers a negative regulation of monocyte activation. These results suggest that diabetes-induced PPARα downregulation in monocytes plays a significant role in monocyte activation and retinal inflammation and, thus, represents a novel therapeutic target for DR.

The PPARα agonist fenofibrate is the first oral drug demonstrating robust therapeutic effects in DR patients, as reported by two large, longitudinal clinical trials (39,40). Our previous studies have reported the effect of fenofibrate on retinal inflammation and vascular leakage in diabetic models (38,41). Its mechanism of action is still not well understood. Our results demonstrate that fenofibrate treatment attenuated the diabetes-induced monocyte activation in diabetic WT mice but not in diabetic PPARα−/− mice, suggesting that fenofibrate suppresses monocyte activation and thus alleviates leukostasis through a PPARα-dependent mechanism. This finding has revealed monocytes as a new drug target of fenofibrate and suggests that inhibition of monocyte activation in diabetes is a new mechanism for the therapeutic effect of fenofibrate on DR.

PPARα is a critical transcriptional factor regulating lipid metabolism and inflammation (42). Global PPARα KO mice develop dyslipidemia (43). We have reported that diabetic global PPARα KO mice demonstrated increased retinal leukostasis relative to diabetic WT mice (38). To exclude possible systemic impacts of dyslipidemia on monocyte activation in global PPARα KO mice, we generated monocyte-specific PPARα conditional KO and transgenic mice for this study. Consistent with the phenotypes from the diabetic global PPARα KO mice, monocyte-specific PPARα conditional KO mice also showed exacerbated retina leukostasis and monocyte activation in diabetes compared with diabetic WT mice. In contrast, transgenic overexpression of PPARα in monocytes alleviated diabetes-induced retinal leukostasis and inhibited monocyte activities. These observations demonstrated that monocytic PPARα is involved in the regulation of monocyte activation and retinal leukostasis in DR.

It is well known that metabolism has important impacts on the function of immune cells (44). Immune cells increase glycolytic ATP production during activation to meet increased energy demands, as declined mitochondrial function and enhanced glycolysis are associated with immune cell activation (44). Mitochondrial dysfunctions have also been related to severe chronic inflammatory disorders (45). In monocytes from diabetic animals or in monocytes treated with 4HNE, mitochondrial function was decreased, while glycolysis was increased, correlating with monocyte activation. Compared with WT, PPARα−/− monocytes have more prominent declined mitochondrial function and increased glycolysis in diabetic and nondiabetic conditions (Supplementary Fig. 4 and Supplementary Tables 4 and 5). The results suggest that PPARα deficiency contributes to mitochondrial functional damage in monocytes and that the subsequent metabolic profile changes could contribute to monocyte activation.

The cGAS-STING pathway is a major pathway regulating inflammation (46). The cGAS-STING pathway is activated and plays a role in diabetic wound healing (47). Its implication in DR, however, has not been documented. The role of this pathway in monocyte activation in diabetes is unknown. The current study investigated the role of the cGAS-STING pathway in monocyte activation in DR. Both our in vitro and in vivo results showed increased levels of cGAS and STING in monocytes from a diabetic model and in primary monocytes exposed to a diabetic stressor. Furthermore, a STING inhibitor and STING KO both attenuated monocyte activation under diabetic conditions. These results provide the first evidence that the cGAS-STING pathway mediates monocyte activation in diabetes and contributes to DR. Interestingly, we also found that fenofibrate attenuated STING activation in monocytes under diabetic conditions, while PPARα KO alone is sufficient to induce the cGAS and STING activation in monocytes, suggesting that PPARα participates in the regulation of the cGAS-STING pathway. Our findings also suggest that suppression of the cGAS-STING activation may represent a molecular mechanism for the anti-inflammatory activity of PPARα.

Cytosolic mtDNA is a known activator of the cGAS-STING pathway (48,49). PPARα is well known to regulate mitochondrial function as well as integrity through regulating PGC-1α and Sirt1 (50,51). To identify the mechanism by which PPARα negatively regulates the cGAS-STING pathway, we measured cytosolic mtDNA release. Diabetes or PPARα KO alone increased cytosolic mtDNA levels in monocytes relative to nondiabetic or WT mice. The increased mtDNA release in the cytosol of diabetic and PPARα−/− monocytes may represent a mechanism for the cGAS-STING pathway activation and monocyte activation induced by diabetes or PPARα deficiency.

In summary, the current study explored the interplay between mitochondria and the innate immune response in DR. We demonstrated a new molecular mechanism through which PPARα regulates the activation of monocytes by directly mediating bioenergy metabolism and protecting mitochondrial integrity and function, especially under diabetic conditions. Our results also revealed a new functional interaction of PPARα with the cGAS-STING pathway. These findings suggest that modulating the cGAS-STING pathway may become a novel therapeutic strategy for the treatment of DR.

This article contains supplementary material online at https://doi.org/10.2337/figshare.22593070.

L.D. and R.C. contributed equally to this work.

Acknowledgments. The authors thank Juping Liu (Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China) for providing samples from patients.

Funding. L.D. received funding from a National Natural Science Foundation of China grant (81570872). J.-x.M. received grants from the National Institutes of Health National Eye Institute (EY019309, EY033330, EY030472, EY012231, EY028949, EY032930, and EY032931). This study was also supported by the Diabetic Animal Core and Histology and Image Core of Diabetic COBRE (GM122744) and the Vision Core supported by the National Eye Institute (P30 EY021725).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. L.D. conducted experiments, acquired data, analyzed data, and wrote the manuscript. R.C. analyzed data and wrote the manuscript. X.M. and W.L. prepared samples. Y.H. and H.L. collected human samples. K.Z. and Y.D. prepared animals. Y.T., X.Z., and X.-r.L. provided reagents. J.-x.M. designed the studies, analyzed data, and wrote the manuscript. J.-x.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

1.
Mesquida
M
,
Drawnel
F
,
Fauser
S
.
The role of inflammation in diabetic eye disease
.
Semin Immunopathol
2019
;
41
:
427
445
2.
Forrester
JV
,
Kuffova
L
,
Delibegovic
M
.
The role of inflammation in diabetic retinopathy
.
Front Immunol
2020
;
11
:
583687
3.
Binet
F
,
Cagnone
G
,
Crespo-Garcia
S
, et al
.
Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy
.
Science
2020
;
369
:
eaay5356
4.
Rezzola
S
,
Corsini
M
,
Chiodelli
P
, et al
.
Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy
.
Diabetologia
2017
;
60
:
719
728
5.
Liu
Y
,
Shen
J
,
Fortmann
SD
,
Wang
J
,
Vestweber
D
,
Campochiaro
PA
.
Reversible retinal vessel closure from VEGF-induced leukocyte plugging
.
JCI Insight
2017
;
2
:
e95530
6.
Joussen
AM
,
Poulaki
V
,
Mitsiades
N
, et al
.
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes
.
FASEB J
2003
;
17
:
76
78
7.
Kohner
EM
,
Patel
V
,
Rassam
SM
.
Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy
.
Diabetes
1995
;
44
:
603
607
8.
Miyamoto
K
,
Ogura
Y
.
Pathogenetic potential of leukocytes in diabetic retinopathy
.
Semin Ophthalmol
1999
;
14
:
233
239
9.
Jaipersad
AS
,
Lip
GY
,
Silverman
S
,
Shantsila
E
.
The role of monocytes in angiogenesis and atherosclerosis
.
J Am Coll Cardiol
2014
;
63
:
1
11
10.
Tabas
I
,
Lichtman
AH
.
Monocyte-macrophages and T cells in atherosclerosis
.
Immunity
2017
;
47
:
621
634
11.
Geissmann
F
,
Manz
MG
,
Jung
S
,
Sieweke
MH
,
Merad
M
,
Ley
K
.
Development of monocytes, macrophages, and dendritic cells
.
Science
2010
;
327
:
656
661
12.
Kuznetsova
T
,
Prange
KHM
,
Glass
CK
,
de Winther
MPJ
.
Transcriptional and epigenetic regulation of macrophages in atherosclerosis
.
Nat Rev Cardiol
2020
;
17
:
216
228
13.
Schinzari
F
,
Tesauro
M
,
Campia
U
,
Cardillo
C
.
Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment
.
Vascul Pharmacol
2020
;
128-129
:
106676
14.
Rangasamy
S
,
McGuire
PG
,
Franco Nitta
C
,
Monickaraj
F
,
Oruganti
SR
,
Das
A
.
Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy
.
PLoS One
2014
;
9
:
e108508
15.
Elsherbiny
NM
,
Sharma
I
,
Kira
D
, et al
.
Homocysteine induces inflammation in retina and brain
.
Biomolecules
2020
;
10
:
393
16.
Hopfner
KP
,
Hornung
V
.
Molecular mechanisms and cellular functions of cGAS-STING signalling
.
Nat Rev Mol Cell Biol
2020
;
21
:
501
521
17.
Sun
L
,
Wu
J
,
Du
F
,
Chen
X
,
Chen
ZJ
.
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway
.
Science
2013
;
339
:
786
791
18.
Yum
S
,
Li
M
,
Fang
Y
,
Chen
ZJ
.
TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections
.
Proc Natl Acad Sci U S A
2021
;
118
:
e2100225118
19.
Ishikawa
H
,
Ma
Z
,
Barber
GN
.
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
.
Nature
2009
;
461
:
788
792
20.
Barbie
DA
,
Tamayo
P
,
Boehm
JS
, et al
.
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
.
Nature
2009
;
462
:
108
112
21.
Varga
T
,
Czimmerer
Z
,
Nagy
L
.
PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation
.
Biochim Biophys Acta
2011
;
1812
:
1007
1022
22.
Pawlak
M
,
Lefebvre
P
,
Staels
B
.
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
.
J Hepatol
2015
;
62
:
720
733
23.
Preidis
GA
,
Kim
KH
,
Moore
DD
.
Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance
.
J Clin Invest
2017
;
127
:
1193
1201
24.
Christofides
A
,
Konstantinidou
E
,
Jani
C
,
Boussiotis
VA
.
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
.
Metabolism
2021
;
114
:
154338
25.
Luo
R
,
Su
LY
,
Li
G
, et al
.
Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model
.
Autophagy
2020
;
16
:
52
69
26.
Bougarne
N
,
Mylka
V
,
Ratman
D
, et al
.
Mechanisms underlying the functional cooperation between PPARα and GRα to attenuate inflammatory responses
.
Front Immunol
2019
;
10
:
1769
27.
Cuzzocrea
S
,
Mazzon
E
,
Di Paola
R
, et al
.
The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation
.
J Leukoc Biol
2006
;
79
:
999
1010
28.
Ginsberg
HN
,
Elam
MB
,
Lovato
LC
, et al.
ACCORD Study Group
.
Effects of combination lipid therapy in type 2 diabetes mellitus
.
N Engl J Med
2010
;
362
:
1563
1574
29.
Keech
A
,
Simes
RJ
,
Barter
P
, et al.
FIELD study investigators
.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
.
Lancet
2005
;
366
:
1849
1861
30.
Ding
L
,
Cheng
R
,
Hu
Y
, et al
.
Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina
.
Am J Pathol
2014
;
184
:
2709
2720
31.
Chen
Y
,
Hu
Y
,
Lin
M
, et al
.
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models
.
Diabetes
2013
;
62
:
261
272
32.
Wang
M
,
Yan
Y
,
Zhang
Z
, et al
.
Programmed PPAR-α downregulation induces inflammaging by suppressing fatty acid catabolism in monocytes
.
iScience
2021
;
24
:
102766
33.
Qiu
F
,
Matlock
G
,
Chen
Q
, et al
.
Therapeutic effects of PPARα agonist on ocular neovascularization in models recapitulating neovascular age-related macular degeneration
.
Invest Ophthalmol Vis Sci
2017
;
58
:
5065
5075
34.
Shao
Y
,
Chen
J
,
Dong
LJ
, et al
.
A protective effect of PPARα in endothelial progenitor cells through regulating metabolism
.
Diabetes
2019
;
68
:
2131
2142
35.
Bernard-Patrzynski
F
,
Lécuyer
MA
,
Puscas
I
, et al
.
Isolation of endothelial cells, pericytes and astrocytes from mouse brain
.
PLoS One
2019
;
14
:
e0226302
36.
Tang
J
,
Kern
TS
.
Inflammation in diabetic retinopathy
.
Prog Retin Eye Res
2011
;
30
:
343
358
37.
McDowell
RE
,
Barabas
P
,
Augustine
J
, et al
.
Müller glial dysfunction during diabetic retinopathy in rats is reduced by the acrolein-scavenging drug, 2-hydrazino-4,6-dimethylpyrimidine
.
Diabetologia
2018
;
61
:
2654
2667
38.
Hu
Y
,
Chen
Y
,
Ding
L
, et al
.
Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction
.
Proc Natl Acad Sci U S A
2013
;
110
:
15401
15406
39.
Kawasaki
R
,
Konta
T
,
Nishida
K
.
Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: a real-world observational analysis of a health claims database
.
Diabetes Obes Metab
2018
;
20
:
2351
2360
40.
Elam
MB
,
Ginsberg
HN
,
Lovato
LC
, et al.
ACCORDION Study Investigators
.
Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes
.
JAMA Cardiol
2017
;
2
:
370
380
41.
Deng
G
,
Moran
EP
,
Cheng
R
, et al
.
Therapeutic effects of a novel agonist of peroxisome proliferator-activated receptor alpha for the treatment of diabetic retinopathy
.
Invest Ophthalmol Vis Sci
2017
;
58
:
5030
5042
42.
Bougarne
N
,
Weyers
B
,
Desmet
SJ
, et al
.
Molecular actions of PPARα in lipid metabolism and inflammation
.
Endocr Rev
2018
;
39
:
760
802
43.
Peters
JM
,
Hennuyer
N
,
Staels
B
, et al
.
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice
.
J Biol Chem
1997
;
272
:
27307
27312
44.
Pearce
EL
,
Pearce
EJ
.
Metabolic pathways in immune cell activation and quiescence
.
Immunity
2013
;
38
:
633
643
45.
Dela Cruz
CS
,
Kang
MJ
.
Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases
.
Mitochondrion
2018
;
41
:
37
44
46.
Decout
A
,
Katz
JD
,
Venkatraman
S
,
Ablasser
A
.
The cGAS-STING pathway as a therapeutic target in inflammatory diseases
.
Nat Rev Immunol
2021
;
21
:
548
569
47.
Geng
K
,
Ma
X
,
Jiang
Z
, et al
.
Innate immunity in diabetic wound healing: focus on the mastermind hidden in chronic inflammatory
.
Front Pharmacol
2021
;
12
:
653940
48.
Aarreberg
LD
,
Esser-Nobis
K
,
Driscoll
C
,
Shuvarikov
A
,
Roby
JA
,
Gale
M
Jr
.
Interleukin-1β induces mtDNA release to activate innate immune signaling via cGAS-STING
.
Mol Cell
2019
;
74
:
801
815.e6
49.
Riley
JS
,
Quarato
G
,
Cloix
C
, et al
.
Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis
.
EMBO J
2018
;
37
:
e99238
50.
Najt
CP
,
Khan
SA
,
Heden
TD
, et al
.
Lipid droplet-derived monounsaturated fatty acids traffic via PLIN5 to allosterically activate SIRT1
.
Mol Cell
2020
;
77
:
810
824.e8
51.
Johri
A
,
Chandra
A
,
Flint Beal
M
.
PGC-1α, mitochondrial dysfunction, and Huntington’s disease
.
Free Radic Biol Med
2013
;
62
:
37
46
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.